Niagen Bioscience, Inc. — Director's Dealing 2022

Mar 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2022-03-16

Reporting Person: Fried Robert N (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-16	Common Stock	P	25000	$2.16	Acquired	88001	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	892314	Direct
Common Stock	250000	Indirect
Common Stock	250000	Indirect
Common Stock	12746	Indirect

Footnotes

F1: The weighted average purchase price for the transaction reported was $2.16, and the range of prices were between $2.14 and $2.16, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided.

F2: On August 4, 2021, 9,753 shares previously owned indirectly by Fried Films Profit Sharing were transferred to Robert N Fried IRRA.

F3: 6,745 shares held by Jeremy Fried and 6,001 shares held by Benjamin Fried, who are sons of Robert Fried.